IntoCell
IntoCell has 1 licensing announcement in this dataset, dated 2026-07-22.
- Country / operating region
- South Korea
- Ticker
- 287840.KQ
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- intocell.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| SBE303 | Nectin-4 | ADC | 查無 | 2026-07-22 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| SBE303 | 查無 | — | 查無 | 查無 | 2026-07-22 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2026-07-22 | Samsung Bioepis | SBE303 | 查無 | 查無 | 查無 | 查無 | Commercial rights agreement; financial terms remain confidential. |
| Counterparty | Territory | Royalties |
|---|---|---|
| Samsung Bioepis | 查無 | 查無 |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無